Therapy Areas: Cardiovascular
Dr. Reddy's Laboratories Launches Fesoterodine Fumarate Extended-Release Tablets in the US Market
8 July 2022 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz (fesoterodine fumarate) Extended-Release Tablets in the US market following the approval by the US Food and Drug Administration, the company said.

The Toviaz brand had US sales of approximately USD 211m MAT for the most recent twelve months ending in May 2022 according to IQVIA.

Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.

Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.

Its major markets include USA, India, Russia and CIS countries, and Europe.


Related Headlines